

## 510(k) Summary

DEC 14 2012

This 510(k) summary is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

**A. Name and Address of Applicant**

Avinger, Inc.  
400 Chesapeake Drive  
Redwood City, CA 94063

**B. Contact Person**

Babu Periasamy  
Manager, Regulatory Affairs and Compliance  
(650) 241-7006

**C. Date Prepared**

November 15, 2012

**D. Device Name**

Trade Name: Ocelot PIXL Catheter  
Common Name: Percutaneous Catheter  
Classification Name: Percutaneous Catheter

**E. Device Classification**

Classification: 21 CFR §870.1250  
Product Code: DQY  
Device Class: Class II

**F. Predicate Device**

The Ocelot PIXL Catheter is substantially equivalent to the original Ocelot Catheter (K122380).

**G. Device Description**

The Ocelot PIXL System consists of the Ocelot PIXL Catheter, the Lightbox Console and the Umbilical. The Ocelot PIXL Catheter is an over-the-wire device that is compatible with a 5F sheath and 0.014" guidewire. The Ocelot PIXL Catheter is available in two different lengths; 135cm working length or 150cm working length and incorporates an optical fiber used to facilitate Optical Coherence Tomography (OCT)-assisted orientation as an adjunct to fluoroscopy.

**H. Intended Use**

The Ocelot PIXL System is intended to facilitate the intraluminal placement of conventional guidewires beyond stenotic lesions (including sub and chronic total occlusions) in the peripheral vasculature prior to further percutaneous intervention using OCT-assisted orientation as an adjunct to fluoroscopy. The Ocelot PIXL System is contraindicated for use in the iliac, coronary, cerebral, renal or carotid vasculature.

**I. Substantial Equivalence**

The Ocelot PIXL Catheter is substantially equivalent to the originally cleared Ocelot Catheter (K122380). The subject and predicate devices have the same mechanism of action (manual advancement) and perform the same function (placement of guidewires beyond stenotic lesions in the peripheral vasculature). The Ocelot PIXL Catheter is a smaller (5F vs. 6F), longer version (150/135cm vs. 110cm) of the Ocelot Catheter. The Ocelot PIXL Catheter's smaller diameter (5F) and working lengths are similar to the Avinger Kittycat and Kittycat 2 Catheters (K120273). The other design changes implemented to create Ocelot PIXL Catheter include a slightly smaller drive shaft and torque shaft, a longer hypotube in the handle assembly, a strain relief just distal to the rotator knob and the addition of a coil around the shaped distal segment. The changes to the Ocelot Catheter cleared under K122338 results in no significant changes to technological characteristics and do not raise any new issues of safety or effectiveness.

**J. Non-Clinical Performance Data**

The following non-clinical testing was previously conducted with the Ocelot PIXL Catheter to support a determination of substantial equivalence to the predicate device.

• Visual and Dimensional Verification	• Spiral Blade Functional Testing
• Tensile Testing	• Coating Friction Testing
• Torque Testing	• Tip Penetration Testing
• Guidewire advancement	• In Vitro Simulated Use Testing
• Device Advancement	• Shelf Life Testing
• Tip Deflection Testing	• Tip-Stall Testing
• Device leak testing	• Tip Penetration Testing
• Luer Leak Testing	• Flexibility/Trackability

The above testing confirmed that the Ocelot PIXL Catheter performs according to the stated intended use. All data fell well within pre-determined product specifications and external standard requirements. Results of non-clinical testing demonstrated that the Ocelot PIXL Catheter is substantially equivalent to the predicate device for the stated intended use.

**K. Conclusions**

The Ocelot PIXL Catheter has been carefully compared to legally marketed devices with respect to intended use and technological characteristics. Non-clinical testing was conducted to validate the performance of the devices and ensure the Ocelot PIXL Catheter functions as intended and meet design specifications. The comparison and non-clinical results demonstrate that the devices are substantially equivalent to the predicate device for the stated intended use.



## DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center – WO66-G609  
Silver Spring, MD 20993-0002

Avinger, Inc.  
Mr. Babu Periasamy  
Manager, Regulatory and Quality Affairs  
400 Chesapeake Drive  
Redwood City, CA 94063

SEP 18 2013

Re: K123532

Trade/Device Name: Ocelot PIXL Catheter  
Regulation Number: 21 CFR 870.1250  
Regulation Name: Percutaneous Catheter  
Regulatory Class: Class II  
Product Code: PDU  
Dated: November 15, 2012  
Received: November 16, 2012

Dear Mr. Periasamy:

This letter corrects our substantially equivalent letter of December 14, 2012.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).

You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

  
*for* Bram D. Zuckerman, M.D.  
Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

**Indications for Use Statement**

510(k) Number (if known): K 123532

Device Name: Ocelot PIXL Catheter

**Indications for Use:**

The Ocelot PIXL System is intended to facilitate the intraluminal placement of conventional guidewires beyond stenotic lesions (including sub and chronic total occlusions) in the peripheral vasculature prior to further percutaneous intervention using OCT-assisted orientation as an adjunct to fluoroscopy. The Ocelot PIXL System is contraindicated for use in the iliac, coronary, cerebral, renal or carotid vasculature.

Prescription Use X      Or      Over-The-Counter Use \_\_\_\_\_  
(per 21 CFR 801.109)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
(Division Sign-Off)  
Division of Cardiovascular Devices  
510(k) Number K123532